# Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

> clinical trial · VERIFIED · 2026-08-03

Status: NOT_YET_RECRUITING · Sponsor: Chinese University of Hong Kong · Condition: Bladder Cancer

- Company: Chinese University of Hong Kong
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07724886

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.